Deutsche Bank set a €133.00 ($154.65) price objective on MorphoSys (ETR:MOR) in a report published on Thursday morning, Borsen Zeitung reports. The firm currently has a buy rating on the stock.
Several other research analysts have also weighed in on MOR. Royal Bank of Canada increased their price objective on from GBX 2,400 ($31.36) to GBX 2,800 ($36.59) and gave the stock an outperform rating in a research report on Monday, June 24th. Berenberg Bank reiterated a hold rating and issued a GBX 1,581 ($20.66) price objective on shares of in a research report on Tuesday, June 11th. JPMorgan Chase & Co. set a €50.00 ($58.14) price objective on Brenntag and gave the stock a buy rating in a research report on Tuesday, July 16th. Independent Research set a €96.00 ($111.63) price objective on MorphoSys and gave the stock a neutral rating in a research report on Thursday, July 4th. Finally, Goldman Sachs Group lowered Metcash from a conviction-buy rating to a neutral rating in a research report on Monday, June 24th. Two analysts have rated the stock with a sell rating, three have issued a hold rating and four have given a buy rating to the company. The company has an average rating of Hold and a consensus target price of €101.67 ($118.22).
MOR stock opened at €100.70 ($117.09) on Thursday. The company has a quick ratio of 7.53, a current ratio of 7.75 and a debt-to-equity ratio of 8.65. The firm has a 50 day moving average of €87.84. The stock has a market capitalization of $3.18 billion and a price-to-earnings ratio of -54.20. MorphoSys has a 1 year low of €76.45 ($88.90) and a 1 year high of €124.90 ($145.23).
MorphoSys AG, together with its subsidiaries, develops and commercializes antibodies and peptides for therapeutic applications in the United States. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 115 drugs for various diseases, such as psoriasis, Alzheimer's diseases, haematological malignancies, solid tumors, hemophilia, multiple myeloma, metabolic diseases, inflamation, thrombosis, brittle bone syndrome, eye diseases, cancers, diabetic eye diseases, blood disorders, and asthma.
Recommended Story: Quick Ratio
Receive News & Ratings for MorphoSys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MorphoSys and related companies with MarketBeat.com's FREE daily email newsletter.